skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia

British journal of ophthalmology, 2023-08, Vol.107 (8), p.1043-1050 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2021-320318 ;PMID: 35264328

Full text available

Citations Cited by
  • Title:
    Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia
  • Author: Fricke, Tim R ; Sankaridurg, Padmaja ; Naduvilath, Thomas ; Resnikoff, Serge ; Tahhan, Nina ; He, Mingguang ; Frick, Kevin D
  • Subjects: Age ; Atropine - therapeutic use ; Contact lenses ; Contact Lenses, Hydrophilic ; Cost control ; Cost estimates ; Disease Progression ; Eye ; Humans ; Life expectancy ; Medicare ; Myopia ; Myopia - drug therapy ; Optics and Refraction ; Productivity ; Public health ; Refraction, Ocular ; Review ; Sensitivity analysis ; Urban areas ; Visual impairment
  • Is Part Of: British journal of ophthalmology, 2023-08, Vol.107 (8), p.1043-1050
  • Description: BackgroundInformed decisions on myopia management require an understanding of financial impact. We describe methodology for estimating lifetime myopia costs, with comparison across management options, using exemplars in Australia and China.MethodsWe demonstrate a process for modelling lifetime costs of traditional myopia management (TMM=full, single-vision correction) and active myopia management (AMM) options with clinically meaningful treatment efficacy. Evidence-based, location-specific and ethnicity-specific progression data determined the likelihood of all possible refractive outcomes. Myopia care costs were collected from published sources and key informants. Refractive and ocular health decisions were based on standard clinical protocols that responded to the speed of progression, level of myopia, and associated risks of pathology and vision impairment. We used the progressions, costs, protocols and risks to estimate and compare lifetime cost of myopia under each scenario and tested the effect of 0%, 3% and 5% annual discounting, where discounting adjusts future costs to 2020 value.ResultsLow-dose atropine, antimyopia spectacles, antimyopia multifocal soft contact lenses and orthokeratology met our AMM inclusion criteria. Lifetime cost for TMM with 3% discounting was US$7437 (CI US$4953 to US$10 740) in Australia and US$8006 (CI US$3026 to US$13 707) in China. The lowest lifetime cost options with 3% discounting were antimyopia spectacles (US$7280, CI US$5246 to US$9888) in Australia and low-dose atropine (US$4453, CI US$2136 to US$9115) in China.ConclusionsFinancial investment in AMM during childhood may be balanced or exceeded across a lifetime by reduced refractive progression, simpler lenses, and reduced risk of pathology and vision loss. Our methodology can be applied to estimate cost in comparable scenarios.
  • Publisher: BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd
  • Language: English
  • Identifier: ISSN: 0007-1161
    EISSN: 1468-2079
    DOI: 10.1136/bjophthalmol-2021-320318
    PMID: 35264328
  • Source: BMJ Open Access Journals
    MEDLINE
    ProQuest Central
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait